ALSO NOTED: FDA bans antibiotic in poultry; TargeGen targets lead drug; Advanced Life Sciences cuts IPO price; and much more...

> The FDA on Thursday banned the antibiotic Baytril in poultry, which belongs to the same drug class as the high-powered human drug Cipro, because of concerns that Baytril's use could lead to antibiotic-resistant infections in people. FDA chief Lester Crawford cited particular concerns about campylobacter bacteria, a growing source of serious illness in humans. It is the first time the FDA has withdrawn a veterinary drug on the basis of antibiotic resistance concerns. Story

> UK health experts warn that drug resistance isn't limited to bacteria. Report

> TargeGen designates topical macular degeneration treatment as its lead drug for clinical development. Release

>Abbot Labs licensee Advanced Life Sciences Holding cuts the price of its initial public offering, plans to issue more shares. Story

> Genzyme seeks US approval for enzyme-replacement treatment for Pompe disease. Release

> EU panel backs Amgen oral mucositis drug, Kepivance. Release

> Nicholas Piramal India launches Phase I trials of its cancer drug molecule, P276-00. Story

And Finally... Medical residents with access to free drug samples prescribed more heavily marketed drugs than residents without free samples, according to an American Journal of Medicine study. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.